Search for the best prices     on the Internet!

Foreword
Introduction
Multimodality Therapy in Gynecologic Oncology 1
Overview of Currently Used Chemosensitivity Test Systems in Gynecologic Malignancies and Breast Cancer 12
Clonogenic Assays for Gynecologic Malignancies. Methodology and Results 24
Short-Term Assay (Radiolabeled DNA-Precursor Uptake Method) in Gynecologic Malignancies. Methodology and Results 30
Use of the Extreme Drug Resistance Assay to Evaluate Mechanisms of Resistance in Ovarian Cancer: Taxol Resistance and MDR-1 Expression 39
The Fluorescent Cytoprint Assay in Gynecological Malignancies and Breast Cancer. Methodology and Results 53
The Identification of Drug Resistance in Ovarian Cancer and Breast Cancer: Application of the MTT Assay 64
In vivo Chemosensitivity Test Models for Gynecologic Malignancies. Methodology and Results 76
Clinical Correlations for Cell Culture Assays Based on the Concept of Total Tumor Cell Kill 82
Assessment of Synergistic and Antagonistic Effects of Chemotherapeutic Agents in vitro 91
ATP-Cell Viability Assay Methodology in Both Fresh Gynecologic Tumors and Cell Lines 108
In vivo/in vitro Correlation of Xenografts in Nude Mice and ATP-Cell Viability Assay 122
Review of Data on Gynecologic Cancer Cell Lines: Potential Applications of ATP-Cell Viability Assays 132
Evaluation of New Drugs and Combinations in Gynecologic Tumors and Cancer Cell Lines with the ATP-Cell Viability Assay 145
Application of the ATP-Cell Viability Assay for Assessment of in vitro Radiation Treatment Response in Gynecologic Cancer Cell Lines 156
Application of the ATP-Cell Viability Assay for Assessment of Biologic Response Modifiers in Gynecologic Cancer 166
Current Status and Future Directions of Chemosensitivity Testing 179
Subject Index 195